Skip to main content
Premium Trial:

Request an Annual Quote

Mammogen: Elizabeth Cormier-May

Mammogen has appointed Elizabeth Cormier-May as its CEO and as a member of the firm's board of directors. Cormier-May is currently cofounder, president, and CEO of Persona Health. Prior to Persona Health, she served as VP and head of commercial operations at Exosome Dx. She has also served in roles at Novartis Pharmaceuticals, Myriad Genetics, Qiagen, and Predictive Biosciences.  

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.